Chronic Obstructive Pulmonary Disease, Pulmonary Embolism
Conditions
Brief summary
To access the clinical usefulness of F1+2 in the diagnosis of PE in patients with AECOPD who require hospitalization. Specifically, to determine whether F1+2 may have an additional value in the subgroup of patients with an abnormal D-dimer,to determine whether it may increase the proportion of patients in whom PE can be safely ruled out and to determine the sensitivity, specificity and NPV of F1+2 at various cut-off values.
Interventions
CT pulmonary angiography to determine PE and laboratory blood tests to determine prothrombin fragments F1+2 in blood of COPD patients
Sponsors
Hillel Yaffe Medical Center
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* COPD exacerbation * Able to give informed consent * Able to perform spirometry
Exclusion criteria
* Known malignancy * Known hypercoagulable state * Receiving anticoagulant treatment * Pregnancy * Renal failure * Allergy to iodine
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Negative Predictive Value of Prothrombin Fragment F1+2 | Six months | Blood test to determine predictive value of Prothrombin Fragment F1+2 in PE diagnosis in hospitalized COPD patients |
Countries
Israel
Contacts
Primary ContactIhab Abdelhai, MD
Outcome results
None listed